肿瘤药学2024，Vol.14Issue(6)：686-694,9.DOI:10.3969/j.issn.2095-1264.2024.06.06
HER2阳性乳腺癌抗HER2治疗研究进展
Advances in anti-HER2 targeted therapy for HER2-positive breast cancer
摘要
Abstract
Breast cancer has become the most common malignant tumor in the world.Among them,human epidermal growth factor receptor 2(HER2)-positive breast cancer accounts for 15%-20%.It is highly malignant and easy to relapse and metastasis in a short time,and is considered as one of the most aggressive types of breast cancer.But with the advent of anti-HER2-targeting drugs,survival has been improved significantly in HER2-positive patients.At present,common anti-HER2 drugs include monoclonal antibodies,tyrosine kinase inhibitors(TKIs)and antique-drug conjugates(ADCs).In terms of treatment options,trastuzumab combined with chemotherapy is the basis for the treatment of HER2-positive breast cancer.Early stage patients with high risk factors can further strengthen targeted therapy to improve prognosis,while ad-vanced patients need to rationally select the appropriate strategy of targeted therapy according to different conditions to achieve longer survival.关键词
乳腺癌/人表皮生长因子受体2/靶向治疗/研究进展Key words
Breast cancer/Human epidermal growth factor receptor 2/Targeted therapy/Research progress分类
医药卫生引用本文复制引用
向泓雨,刘荫华..HER2阳性乳腺癌抗HER2治疗研究进展[J].肿瘤药学,2024,14(6):686-694,9.基金项目
中国乳腺癌靶向治疗研究基金项目(KC2021-JF-0167-24). （KC2021-JF-0167-24）
